Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Oncopeptides AB (publ)
  6. Summary
    ONCO   SE0009414576

ONCOPEPTIDES AB (PUBL)

(ONCO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Stockholm
09/22/2021 09/23/2021 09/24/2021 09/27/2021 09/28/2021 Date
44.98(c) 44(c) 43.66(c) 43.94(c) 43.04 Last
277 833 279 669 415 137 325 734 361 270 Volume
-0.09% -2.18% -0.77% +0.64% -2.05% Change
More quotes
Estimated financial data (e)
Sales 2021 325 M 37,2 M 37,2 M
Net income 2021 -1 066 M -122 M -122 M
Net cash position 2021 600 M 68,7 M 68,7 M
P/E ratio 2021 -3,01x
Yield 2021 -
Sales 2022 946 M 108 M 108 M
Net income 2022 -905 M -104 M -104 M
Net cash position 2022 695 M 79,5 M 79,5 M
P/E ratio 2022 -4,24x
Yield 2022 -
Capitalization 3 308 M 379 M 378 M
EV / Sales 2021 8,33x
EV / Sales 2022 2,76x
Nbr of Employees 313
Free-Float 94,3%
More Financials
Company
Oncopeptides AB is a Sweden-based biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The CompanyÔÇÖs lead product candidate PEPAXTO (melphalan flufenamide, also known as melflufen) has been approved in relapsed or refractory multiple myeloma by The U.S. Food and Drug Administration. Melphalan flufenamide is the first drug originated from the Company... 
Sector
Biotechnology & Medical Research
Calendar
11/04 | 02:00amEarnings Release
More about the company
Ratings of Oncopeptides AB (publ)
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C+
More Ratings
All news about ONCOPEPTIDES AB (PUBL)
09/15MAGLE CHEMOSWED : establishes a manufacturing agreement with Oncopeptides
AQ
09/15ONCOPEPTIDES : Handelsbanken Healthy Hour - presentation
PU
09/13ONCOPEPTIDES : Drug Combo Improves Survival in Blood Cancer Patients
MT
09/11ONCOPEPTIDES : presents phase 3 OCEAN study results at the IMW meeting
AQ
09/11Oncopeptides AB Presents Phase 3 Ocean Study Results At the IMW Meeting
CI
09/09ONCOPEPTIDES : Webcast for presentation of OCEAN data presented at IMW
PU
09/09ONCOPEPTIDES : Invitation to webcast for presentation of OCEAN data presented at IMW
AQ
09/09Certain Shares of Oncopeptides AB are subject to a Lock-Up Agreement Ending on 9-SEP-20..
CI
09/02ONCOPEPTIDES : Regulatory update from US Food and Drug Administration
AQ
09/02Oncopeptides AB Announces Regulatory Update from US Food and Drug Administration
CI
08/27ONCOPEPTIDES : presents new data from OCEAN and PORT study - abstracts online
AQ
08/27Oncopeptides AB Presents New Data from OCEAN and PORT Study - Abstracts Online
CI
08/19ONCOPEPTIDES : Financial Reporting Document
PU
08/19ONCOPEPTIDES : publishes report for Q2 2021
AQ
08/19Oncopeptides AB Publ Reports Earnings Results for the Second Quarter Ended June 30, 202..
CI
More news
News in other languages on ONCOPEPTIDES AB (PUBL)
09/13Une combinaison de médicaments à base d'oncopeptides améliore la survie des patients at..
07/19AVIS D'ANALYSTES DU JOUR : Roche, Credit Suisse, Scor, ArgenX, Siemens Gamesa, Prosus, Pum..
07/19MADRID STOCK EXCHANGE : El plan no sale exactamente como estaba previsto
07/19STOCK MARKET PARIS : Le plan ne se déroule pas tout à fait comme prévu
05/27STOCK MARKET PARIS : La sieste n'a pas l'air finie
More news
Chart ONCOPEPTIDES AB (PUBL)
Duration : Period :
Oncopeptides AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ONCOPEPTIDES AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 43,94 SEK
Average target price 89,25 SEK
Spread / Average Target 103%
EPS Revisions
Managers and Directors
Martin J. Duvall Chief Executive Officer
Anders Martin-L÷f Chief Financial Officer & Deputy CEO
Per Wold-Olsen Chairman
Stig Anders Jakob Lindberg Chief Scientific Officer
Fredrik Lehmann Head-Research, Chemistry, Manufacturing & Control
Sector and Competitors
1st jan.Capi. (M$)
ONCOPEPTIDES AB (PUBL)-74.11%380
GILEAD SCIENCES, INC.20.85%88 281
BIONTECH SE276.71%74 169
WUXI APPTEC CO., LTD.35.04%69 209
REGENERON PHARMACEUTICALS28.14%64 363
VERTEX PHARMACEUTICALS-22.40%47 582